AbbVie (ABBV) announced the global Phase 3 Vevrona trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome did not meet the primary endpoint of overall survival with a hazard ratio of 0.908; stratified log-rank. No new safety signals were observed. Results from the Verona trial will be available in a future medical congress and/or publication. Any patients who received venetoclax in combination with azacitidine through participation in the MDS clinical trials will be informed by their treating physician. These data do not impact any current approved indications for venetoclax.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie’s Promising Growth: A Buy Rating Backed by Robust R&D and Strategic Advancements
- Balanced Outlook for AbbVie: Hold Rating Amid Opportunities and Challenges
- AbbVie announces FDA approval for MAVYRET expanded indication
- AbbVie call volume above normal and directionally bullish
- AbbVie’s Promising Growth Trajectory: Strong Pipeline, Strategic Investments, and Global Expansion